Atazanavir: a Review of Its Use in the Management of HIV-1 Infection

Overview

Journal Drugs

Specialty Pharmacology

Date 2009 Jun 6

PMID 19496633

Citations 29

Authors

Katherine F Croom

Sohita Dhillon

Susan J Keam

Affiliations

Soon will be listed here.

Abstract

Atazanavir (Reyataz), a protease inhibitor (PI), is approved in many countries for use as a component of antiretroviral therapy (ART) regimens for the treatment of adult, and in some countries in paediatric, patients with HIV-1 infection. ART regimens containing ritonavir-boosted atazanavir improved virological and immunological markers in adult patients with HIV-1 infection, and had similar efficacy to regimens containing lopinavir/ritonavir in treatment-naive and treatment-experienced patients. In addition, unboosted atazanavir was noninferior to ritonavir-boosted atazanavir in treatment-naive patients. Atazanavir is administered once daily and has a low capsule burden. Atazanavir, whether unboosted or boosted, was generally well tolerated and appeared to be associated with less marked metabolic effects, including less alteration of lipid levels, than other PIs. These properties mean that boosted atazanavir, and unboosted atazanavir in patients unable to tolerate ritonavir, continues to have a role as a component of ART regimens in patients with HIV-1 infection.

Citing Articles

New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.

Marra M, Catalano A, Sinicropi M, Ceramella J, Iacopetta D, Salpini R Viruses. 2024; 16(9).

PMID: 39339960 PMC: 11437459. DOI: 10.3390/v16091484.

Antiretroviral action of Rosemary oil-based atazanavir formulation and the role of self-nanoemulsifying drug delivery system in the management of HIV-1 infection.

Kumar S, Taumar D, Gaikwad S, More A, Nema V, Mukherjee A Drug Deliv Transl Res. 2023; 14(7):1888-1908.

PMID: 38161197 DOI: 10.1007/s13346-023-01492-8.

Factors Associated with Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed with HIV-1 between 2010 and 2018 in Israel.

Wagner T, Levy I, Elbirt D, Shahar E, Olshtain-Pops K, Elinav H Viruses. 2023; 15(12).

PMID: 38140680 PMC: 10748212. DOI: 10.3390/v15122439.

A Review of the Lidocaine in the Perioperative Period.

Silva A, Mourao J, Vale N J Pers Med. 2023; 13(12).

PMID: 38138926 PMC: 10744742. DOI: 10.3390/jpm13121699.

Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals.

Sadat Mousavi Maleki M, Sardari S, Ghandehari Alavijeh A, Madanchi H Int J Pept Res Ther. 2022; 29(1):5.

PMID: 36466430 PMC: 9702942. DOI: 10.1007/s10989-022-10477-z.

References

King J, Kakuda T, Paul S, Tse M, Acosta E, Becker S . Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol. 2007; 47(2):201-8. DOI: 10.1177/0091270006296763. View

Sanne I, Piliero P, Squires K, Thiry A, Schnittman S . Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003; 32(1):18-29. DOI: 10.1097/00126334-200301010-00004. View

Busti A, Tsikouris J, Peeters M, Das S, Canham R, Abdullah S . A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006; 7(5):317-22. DOI: 10.1111/j.1468-1293.2006.00382.x. View

Smith D, Jeganathan S, Ray J . Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006; 7(1):34-8. DOI: 10.1310/0KX0-H9VH-99EE-5D0L. View

Dube M, Shen C, Greenwald M, Mather K . No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis. 2008; 47(4):567-74. PMC: 2919310. DOI: 10.1086/590154. View

Simpson K, Jones W, Rajagopalan R, Dietz B . Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17. DOI: 10.2165/00044011-200727120-00002. View

Gazzard B, Anderson J, Babiker A, Boffito M, Brook G, Brough G . British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008; 9(8):563-608. DOI: 10.1111/j.1468-1293.2008.00636.x. View

Jemsek J, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V . Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2005; 42(2):273-80. DOI: 10.1086/498505. View

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

10.

Cleijsen R, van de Ende M, Kroon F, Lunel F, Koopmans P, Gras L . Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007; 60(4):897-900. DOI: 10.1093/jac/dkm298. View

11.

Murphy R, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T . Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003; 17(18):2603-14. DOI: 10.1097/00002030-200312050-00007. View

12.

Klimas N, Koneru A, Fletcher M . Overview of HIV. Psychosom Med. 2008; 70(5):523-30. DOI: 10.1097/PSY.0b013e31817ae69f. View

13.

Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez-Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J . Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2006; 21(1):41-6. DOI: 10.1097/QAD.0b013e328011d7c1. View

14.

Kumar P, Salvato P, LaMarca A, DeJesus E, Patel P, Mcclernon D . A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION.... AIDS Res Ther. 2009; 6:3. PMC: 2672933. DOI: 10.1186/1742-6405-6-3. View

15.

Seminari E, Guffanti M, Villani P, Gianotti N, Cusato M, Fusetti G . Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol. 2005; 61(7):545-9. DOI: 10.1007/s00228-005-0966-x. View

16.

Simpson K, Rajagopalan R, Dietz B . Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009; 26(2):185-93. DOI: 10.1007/s12325-008-0141-8. View

17.

Cohen C, Nieto-Cisneros L, Zala C, FESSEL W, Gonzalez-Garcia J, Gladysz A . Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin. 2005; 21(10):1683-92. DOI: 10.1185/030079905x65439. View

18.

Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M . Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS. 2007; 21(13):1826-8. DOI: 10.1097/QAD.0b013e3282742000. View

19.

von Hentig N, Muller A, Rottmann C, Wolf T, Lutz T, Klauke S . Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother. 2007; 51(4):1431-9. PMC: 1855477. DOI: 10.1128/AAC.00854-06. View

20.

Powderly W . Limitations of current HIV therapies: opportunities for improvement. J Acquir Immune Defic Syndr. 2003; 33 Suppl 1:S7-12; quiz S13, 15-6. DOI: 10.1097/00126334-200306011-00002. View